We use cookies to ensure that we give you the best experience on our website.

Cookies Notice

WHAT IS COOKIE?

A cookie is a small piece of text that allows a website to recognize your device and maintain a consistent, cohesive experience throughout multiple sessions. If you visit EDAN pages, both EDAN and third parties will use cookies to track and monitor some of your activities, and store and access some data about you, your browsing history, and your usage of the EDAN pages.


HOW DOES EDAN USE COOKIES?

This policy describes how both EDAN and other third parties use cookies and how you can exercise a greater degree of control over cookies. Please keep in mind that this may alter your experience with our website, and may limit certain features.


General Browsing: We use cookies that are important for certain technical features of our website, like implementing fixes and improvements to our platform.

These cookies:

    - Enable behavior in our Products or Services that is tailored to the activity or preferences of a person visiting our properties

    - Allow users to opt out of certain types of modeling or personalization in our products

    - Collect information on our users’ preferences in order to create more useful products

    - Maintain the regular business operations of our Advertising and Marketing departments

    - Help to diagnose and correct downtime, bugs, and errors in our code to ensure that our products are operating efficiently


Analytics: We use cookies to compile usage activity in order to better cater our Products and Services offerings to you, and to third parties. We DO NOT share identifiable “raw” data with our clients or any third parties, however we do make high-level decisions based on aggregated data about your usage of our Products and Services.


These cookies:

    - Monitor site traffic and behavior flows of users

    - Measure the effectiveness of products

    - Measure the effectiveness of off-site marketing campaigns and tactics


WHAT INFORMATION IS COLLECTED ON ME VIA COOKIES?

In general, we collect most data from you via form submission. However, there are cases when visiting our site and/or using our platforms in which we may receive certain information through the use of cookies. This data will generally not include personally identifying information about you.

    - Unique identification tokens

    - User preferences such as favorite tags (for anonymous users only)


Third Party Cookies

The use of cookies, the names of cookies, and other cookies related cookies technology may change over time and EDAN will make all reasonable efforts to notify you by updating our cookies table where material changes occur and from time-to-time.


HOW DO I RESTRICT COOKIES?

If you don’t want EDAN to use cookies when you visit EDAN home pages, you can opt-out of certain cookie related processing activities when you visit the pages. If you opt-out of cookies, we have to set a cookie to tell us that. Please note that EDAN may not work properly and you may have diminished functionality if you opt-out of certain cookies.If you decide that you do not want cookies to be set on your device by our third-party Partners, you can adjust the settings on your internet browser and choose from the available Cookies setting to best meet your preferences. While setting options may vary from browser to browser, you can generally choose to reject some or all cookies, or instead to receive a notification when a cookie is being placed on your device. For more information, please refer to the user help information for your browser of choice. Please keep in mind that cookies may be required for certain functionalities, and by blocking these cookies, you may limit your access to certain parts or features of our sites. You can manually delete the cookies at any time.

选择另一个国家或地区,以获得适用于你所在位置的内容和在线购物选项。
中文
继续

Performance of the EDAN H50 on Eosinophil Samples

Accurate counting and differentiation of eosinophils from white blood cells are not as simple as you think. While with the combination of the flow-cell, the super blue LED, and the proprietary reagents, the EDAN H50 provides excellent results on eosinophilia samples.

World Allergy Day 2021

Excellent performance of the EDAN H50 on Eosinophil samples

Treatments that specifically target eosinophils are likely to be effective in controlling a number of important and prevalent diseases in the fields of allergy, infectious disease, autoimmunity and malignancy. However, accurate counting and differentiation of eosinophil from white blood cells is not as simple as you think.

While with the combinaiton of the flow-cell, the super blue LED, and the proprietary reagents, the EDAN H50 provides excellent results on eosinophilia samples.

"The prevalence of allergic diseases worldwide is rising dramatically in both developed and developing countries. Up to 10% to 40% of the whole population suffer from allergy disease. This increase is especially problematic in children, who are bearing the greatest burden of the rising trend which has occurred over the last two decades."

ALLERGY FACTS AND FIGURES

The World Allergy Organization (WAO) estimates of allergy prevalence of the whole population by country ranges between 10% - 40%.

More than 150 million Europeans suffer from chronic allergic diseases and the current prediction is that by 2025 half of the entire EU population will be affected.

More than 50 million Americans have experienced various types of allergies each year and allergies are the 6th leading cause of chronic ilness in the U.S.

10%- 25% of total population in Africa have one or more allergy diseases. 25% of total population in Albania, 15% of total popula-tion in Algeria, 10% of the adult population and 25% of the childhood population in South Africa, 7 of adult population and 20% of childhood population in Egypt.

15% 30% of total population in Latin America suffer from one or more allergy disease. 20%-30% of childhood population in Brazil, 20% of the total population in Argentina, 15% of the total population in Chile, 30% of adult population and 42% of childhood population in Paraguay.

10%- 30% of total population in Asia and the Middle East suffer from one or more al-lergy disease. 10%-15% of childhood pop-ulation in Malaysia, 30% of adult population and 40% of childhood population in South Korea, 33.7% of childhood population in Sri Lanka, 10% of total population in Thailand. 20%-30% of total population in India, 15%

of the total population in Israel, 20% - 30% of total population in Jordan, 15% of total population in Turkey.

“Allergy is a very common chronic disease. The complexity and severity of allergic diseases, including asthma, continue to increase especially in children and young adults. Those who have allergy diseases should be taken carefully, or may cause major disability, and are costly both to the individual and to their society."

ALLERGY TYPES

Allergic diseases include life-threatening anaphylaxis, food allergies, certain forms of asthma, rhinitis, conjunctivitis, angioedema, urticarial, eczema,eosinophilic disorders, including eosinophilic esophagitis, and drug and

insect allergies.

300 million individuals have asthma worldwide

240 - 550 million people may suffer from food allergy

Affects up to 10% of the world's population and 20% of all hospitalized patients

Affects between 10% and 30% of the population

Eosinophilic Esophagitis

TARGETING EOSINOPHILS IN ALLERGY, INFLAMMATION AND BEYOND

Eosinophilia, defined as a peripheral blood eosinophil count greater than 450 cells per microliter, is associated with numerous

disorders including allergies, drug reactions, eosinophilic gastrointestinal disorders, and hyper eosinophilic syndrome.

Eosinophil-rich inflammation has long been associated with parasitic infestation and allergic inflammation. A body of

evidence including clinical studies and animal models of asthma has demonstrated a causal role for eosinophils in asthma

pathogenesis including airway hyper-reactivity, elevated mucus production and airway remodeling.

These studies include elegant experiments in eosinophil-lineage-deficient mice that have protection against features of asthma, although not in all cases. Clinical studies have revealed an important role for eosinophils in asthma exacerbations. Recent evidence also supports a broader role for eosinophils in health and disease with their emerging role in malignancy

and in regulating antibody production. In addition, eosinophils can fre-quently be found surrounding solid tumors and can participate in tumor immune surveillance influencing the incidence of tumor formation.Recent studies have proposed a role for eosinophils in humoral immunity as an important source of pro-survival factors for long-lived plasma cells in

the bone marrow. In autoimmune disease in which plasma cells have a pathologic role via autoantibody production, eosinophils may prove to be an attractive therapeutic target. Thus, treatments that specifically target

eosinophils are likely to be effective in controlling a number of important and prevalent diseases in the fields of allergy, infectious disease, autoimmunity and malignancy.

EXCELLENT PERFORMANCE OF THE EDAN H50 ON EOSINOPHILIA SAMPLES

Accurate counting and differentiation of eosinophil from white blood cells is not as simple as you think. While with the combination of the flow-cell, the super blue LED, and the proprietary reagents, the EDAN H50 provides

excellent results on eosinophilia samples.

On World Allergy Day 2020, let's target on eosinophil to help allergic people.

H50 Hematology Analyzer

I. Pawankar R, Canonica GW, ST Holgate ST, Lockey RF, Blaiss M: The WAO White Book on Allergy (Update. 2013).

2. CDC, Gateway to Health Communication and Social Marketing Practice. Allergies.

htps://ww .cdc gov/healthcommunicationtoolstemplates/enter-tainmentedltips/Allergies .html (Rerrieved March 14 2018))

3. Fulkerson, P. C, & Rothenberg, M. E. (2013). Targeting eosinophils in allergy,inflammation and beyond. Nature reviews. Drug discovery, 12(2), 117-129.htps://i./ org/10.1038/nrd3838

Company NewsExhibitions & EventsCOVID-19Product Insights
Product Insights

Excellent Performance of the EDAN H50 on Eosinophil Samples

07.08-2021

WechatIMG449.jpg

2020 World Allergy Day.jpg